Associations between homocysteine and coagulation factors--a cross-sectional study in two populations of central Europe.

[1]  B. Horne,et al.  Plasma Homocysteine Predicts Mortality Independently of Traditional Risk Factors and C-Reactive Protein in Patients With Angiographically Defined Coronary Artery Disease , 2000, Circulation.

[2]  J. Herlitz,et al.  Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. , 2000, Archives of internal medicine.

[3]  H. Philippou,et al.  Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. , 2000, Circulation.

[4]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[5]  R. Marfella,et al.  Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. , 1999, JAMA.

[6]  J. Loscalzo,et al.  Homocysteine and atherothrombosis. , 1998, The New England journal of medicine.

[7]  A. Folsom,et al.  Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. , 1998, Circulation.

[8]  L. Kuller,et al.  Homocysteine, vitamins, and cardiovascular disease. , 1998, Circulation.

[9]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[10]  B. McManus,et al.  Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background , 1997 .

[11]  A. Kaider,et al.  Levels of Prothrombin Fragment F1+2 in Patients with Hyperhomocysteinemia and a History of Venous Thromboembolism , 1997, Thrombosis and Haemostasis.

[12]  K. Woo,et al.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 1997, Circulation.

[13]  J. Cutler,et al.  Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[15]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[16]  P. Mannucci,et al.  Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. , 1997, Circulation.

[17]  P. Harpel.  Homocysteine, atherogenesis and thrombosis , 1997 .

[18]  S. Javorschi,et al.  Mild Hyperhomocysteinemia and Hemostatic Factors in Patients with Arterial Vascular Diseases , 1997, Thrombosis and Haemostasis.

[19]  W C Willett,et al.  Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. , 1996, American journal of epidemiology.

[20]  P. Reitsma,et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. , 1996, The New England journal of medicine.

[21]  S. Ebrahim,et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men , 1995, The Lancet.

[22]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[23]  A. Haeberli,et al.  Fibrin Formation and Degradation in Patients With Arteriosclerotic Disease , 1994, Circulation.

[24]  P. Ridker,et al.  Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. , 1994, Circulation.

[25]  K. Robinson,et al.  Homocysteine and coronary artery disease. , 1994, Cleveland Clinic journal of medicine.

[26]  A. von Eckardstein,et al.  Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. , 1994, Arteriosclerosis and Thrombosis A Journal of Vascular Biology.

[27]  K. Shimada,et al.  Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. , 1993, The Journal of clinical investigation.

[28]  K. Hajjar.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. , 1993, The Journal of clinical investigation.

[29]  E. Ernst.  The role of fibrinogen as a cardiovascular risk factor. , 1993, Atherosclerosis.

[30]  L. Tavazzi,et al.  The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[31]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[32]  J. Sadler,et al.  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. , 1991, The Journal of clinical investigation.

[33]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[34]  G. Rodgers,et al.  Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. , 1990, Blood.

[35]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[36]  D. Rylatt,et al.  Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems , 1985, British journal of haematology.

[37]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[38]  R. Ross,et al.  Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. , 1983, Circulation research.

[39]  R. Ross,et al.  Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. , 1976, The Journal of clinical investigation.

[40]  P. Ueland,et al.  Plasma Homocysteine and Cardiovascular Disease , 2000 .

[41]  G. Lowe,et al.  Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[42]  G. Moneta,et al.  Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. , 1999, Journal of vascular surgery.

[43]  R. D'Agostino,et al.  Prothrombotic and reduced fibrinolytic state in association with homocysteinemia: the framingham offspring study , 1998 .

[44]  A. von Eckardstein,et al.  The emergence of triglycerides as a significant independent risk factor in coronary artery disease. , 1998, European heart journal.

[45]  C. Stehouwer,et al.  Endothelial Marker Proteins in Hyperhomocysteinemia , 1997, Thrombosis and Haemostasis.

[46]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .